Læknablaðið - 15.12.2008, Qupperneq 24

ENGLISH SUMMARY
■ FRÆÐIGREINAR
Y F I R L I T
12. Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating
peritonitis in patients undergoing continuous ambulatory peritoneal
dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis
Study Group. Am J Kidney Dis 1996; 28:420-7.
13. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in
Australia. Nephrol Dial Transplant 1998; 13:154-9.
14. Summers AM, Clancy MJ, Syed F, et al. Single-center experience of
encapsulating peritoneal dialysis for end-stage renal failure. Kidney Int
2005; 68:2381-8.
15. Korte MR, Yo M, Betjes MGH, et al. Increasing incidence of severe
encapsulating peritoneal sclerosis after kidney transplantation.
Nephrol Dial Transplant 2007; 22: 2412-4.
16. Xu P, Chen LH, Li YM. Idiopathic sclerosing encapsulating peritonitis
(or abdominal cocoon): a report of 5 cases. World J Gastroenterol 2007;
13: 3649-51.
17. Rottembourg J, Gahl GM, Poignet JL, et al. Severe abdominal
complications in patients undergoing continuous ambulatory peritoneal
dialysis. Proceedings of the Europian Dialysis and Transplantation
Assocociation 1983; 20: 236-42.
18. Junor BJR, Briggs JD, Forewell MA, Dobbie JW, Henderson I. Sclerosing
peritonitis - the controbution of chlorhexidine in alcohol. Peritoneal
Dialysis Bulletin 1985; 5:101-4.
19. Gillerot G, Devuyst O. Molecular mechanisms modifying the peritoneal
membrane exposed to peritoneal dialysis. Clin Nephrol 2003; 60:106.
20. Yamamoto R, Nakayama M, Hasegawa T, et al. High-transport
membrane is a risk factor for encapsulating peritoneal sclerosis
developing after long-term continuous ambulatory pertoneal dialysis
treatment. Adv Perit Dial 2002; 18:131-4.
21. Kawaguchi Y, Saito A, Kawanishi H, et al. Recommendations on the
management of encapsulating peritoneal sclerosis in Japan, 2005:
diagnosis, predictive markers, treatment, and preventive measures.
Perit Dial Int 2005; 25; S83-S95.
22. Saito A. Peritoneal dialysis in Japan: the issue of encapsulating
peritoneal sclerosis and future challenges. Perit Dial Int 1999; 2005:
25(suppl 4): S77-82.
23. Arnadottir M, Alm P, Simonsen S, Rippe B. Skleroserande peritonit
- en sállsynt men allvarlig komplikation vid peritonealdialys.
Lákartidningen 1992; 89:3665-8.
24. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances
transforming growth factor beta 1 expression and promotes tumor
progression. Transplantation 2003; 76:597-602.
25. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S.
Expression of TGF-beta and fibrogenic genes in transplant recipients
with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62:
2257-64.
26. Numata M, Nakayama M, Hosoya T, et al. Possible pathologic
involvement of receptor for advanced glycation end products (RAGE)
for development of encapsulating peritoneal sclerosis in Japanese
CADP patients. Clin Nephrol 2004, 62:455-60
27. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the
peritoneal membrane of patients with renal disease. J Am Soc Nephrol
2002; 13:470-9.
28. Courtney AE, Doherty CC. Fulminant sclerosing peritonitis immediately
following acute bacterial peritonitis. Nephrol Dial Transplant 2006; 21:
532-4
29. Courtney AE, Doherty CC. Single-center experience of encapsulating
peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal
failure. Kidney Int 2006; 69:1094.
30. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential
effect of sirolimus vs prednisolone in the treatment of sclerosing
encapsulating peritonitis. Nephrol Dial Transplant 2002; 17:2278-80.
31. Evrenkaya TR, Atasou EM, Unver S, Basekim C, Baloglu H, Tulbek
MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating
peritonitis in a patient on continuous ambulatory peritoneal dialysis.
Nephrol Dial Transplant 2004; 19: 2423-4.
32. Michael C, Hufnagel G, Niang A, et al. Sclerosing peritonitis.
Nephrologie 2001; 22:141-8.
33. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case
of a dialysis patient with sclerosing peritonitis successfully treated with
corticosteroid therapy alone. Am J Kidney Dis 1997; 30:275-8.
34. Georg C, Al-Zwae K, Nair S, Cast JEI. Computed tomography
appearances of sclerosing encapsulating peritonitis. Clin Radiol 2007;
61:732-7.
35. Duman S, Ozbek SS, Gunay ES, et al. What does peritoneal thickness
in peritoneal dialysis patients tell us? Advances in peritoneal dialysis
2007; 23: 28-33.
36. Wong CF, Beshir S, Khalil A, Pai R, Ahmad R. Successful treatment of
encapsulating peritoneal sclerosis with azathioprine and prednisolone.
!!!!
37. Lafrance JP, Létourneau I, Ouimet D, et al. Successful treatment of
encapsulating peritoneal sclerosis with immunosuppressive therapy.
Am J Kidney Dis 2008; 51: E7-10.
38. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C. Long-term
outcome of idiopathic retroperitoneal fibrosis treated with surgical
and/or medical approaches. Nephrol Dial Transplant 2006; 21: 2485-
90.
39. Wong CF. Clinical experience with tamoxifen in encapsulating
peritoneal sclerosis. Perit Dial Int 2006; 26; 183-4.
40. del Peso G, Bajo AM, Gil F, et al. Clinical experience with tamoxifen in
peritoneal syndromes. Adv Perit Dial 2003; 19: 32-5.
41. Moustafellos P, Hadjanastassiou V, Roy D, Velzzeboes NE. Tamoxifen
therapy in encapsulating sclerosing peritonitis in patients after kidney
transplantation. Transplant Proc 2006; 38: 2913-4.
42. Kawanishi H, Kawaguchi Y. Prevalence and therapeutic outcome of
sclerosing encapsulating peritonitis (EPS) - a multicenter study in
Japan. Jin To Toseki 2000; 49:225-8.
43. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical
management of encapsulating peritoneal sclerosis. Perit Dial Int 2005;
25: S39-S47.
44. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases
of encapsulating peritoneal sclerosis: investigation of recurrent cases
after surgery. Advances in Perit Dial 2007; 22: 60-4.
45. Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility:
definitions and evaluation strategies. Kidney Int 2003; 64 (Suppl 88):
S50-56.
46. Chan TM, Yung S. Studying the effects of new peritoneal dialysis
solutions on the peritoneum. Perit Dial Int 2007; 27(Suppl 2):
47. Summers AM, Brenchley PEC. An international encapsulating
peritoneal sclerosis registry and DNA bank: why we need one. Perit
Dial Int 2006; 26: 559-63.
48. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphological
changes of peritoneum and expression of VEGF in encapsulated
peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
49. Hekking LH, Harvey VS, Havenith CE, van den Bom J, et al.
Mesothelial cell transplantation in models of acute inflammation and
chronic peritoneal dialysis. Perit Dial Int 2003; 23: 323-30.
Encapsulating peritoneal scierosis
The incidence of encapsulating peritoneal sclerosis in
patients on peritoneal dialysis seems to be increasing
worldwide. In lceland, two cases of encapsulating
peritoneal sclerosis have recently been diagnosed
(cumulative incidence 1.6%). The patients foilowed a
similar course; the disease was diagnosed in the wake
of a bacterial peritonitis, steroid treatment was effective
during the acute phase but eventually surgical treatment
was needed and a successful enterolysis performed.
Key words: encapsulating peritoneal sclerosis, peritoneal dialysis, peritonitis.
Arnadottir M, Elvarsson F, Indridason OS, Olafsson L, Jonasson JG, Möller PH. Encapsulating peritoneal sclerosis. Icel Med J
2008; 94: 815-20.
Correspondence: Margrét Arnadóttir, margarn@landspitali.is
Barst: 2. maí 2008, - samþykkt til birtingar: 6. nóvember.
820 LÆKNAblaðið 2008/94